报告题目：Cancer Drug Resistance and Drug Discovery: from DNA damage response to Purine Biosynthesis

报告人：周斌兵 教授，上海交大医天美

主持人👩‍🍼：翁杰敏 教授

报告时间🚭：2018年11月12日 14:30

报告地点：天美娱乐534小会议室

报告人简介：Dr. Zhou is Director, Pediatric Translational Medicine Institute; Chair, Department of Pharmacology and Chemical Biology, Shanghai Jiaotong University School of Medicine.  Current research interests include DDR as a barrier for childhood leukemia relapse, interaction between DDR and purine biosynthesis pathway.  The first part of the study was published as a cover story in Nature Medicine in 2015.

Before recruited back to China by the National Thousand Talents Program in 2012, he was Senior Director of Oncology Research, Pfizer Inc in US. He has been interested in cancer drug discovery and drug resistance mechanism over the years, and has contributed to two approved (Tykerb and Besponsa), two Phase II clinical trial anti-cancer agents.  In academic community, he is best known for his proposal of DNA damage response (DDR) hypothesis in collaboration with Dr. Stephen Elledge. He received BS from Fudan University, PhD from University of California, Berkeley, and was a postdoctoral fellow with Marc Kirschner at Harvard Medical School. He received many awards including UC Berkeley University Fellowship, Helen Hay Whitney Fellowship, SAPA (Sino-American Pharmaceuticals Professionals Association) Achievement Award, China National Thousands Talent Award.